在膀结石相关状细胞癌中对PD-1抑制剂的持久完整反应:一个病例报告
Xingwang Dong1, Xiaobao Fu2, Hanghao Zhang3
1Department of Urology, Gannan Tibetan Autonomous Prefecture People's Hospital, Hezuo, China.
Frontiers in immunology
|December 8, 2025
概括
作为PD-1抑制剂的tislelizumab为化学疗法不耐受患者的结石相关膀平细胞癌 (SCC) 提供了潜在的治疗方法. 这种方法可以在免疫疗法期间安全地进行手术去除石头,没有观察到复发.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 膀平细胞癌 (SCC) 是一种罕见的癌症,占病例的1%-5%.
- 彻底囊切除术是标准的治疗方法,但新辅助/辅助化疗或免疫治疗的证据有限,特别是在结石相关的SCC.
研究的目的:
- 评估tislelizumab单一治疗在患有结石相关膀SCC的患者的疗效和安全性,该患者无法接受手术和放射治疗,不能接受化疗.
- 评估免疫疗法期间同时进行上皮囊切除术的可行性.
主要方法:
- 一名45岁的男性患有膀结石相关的膀SCC,每3周服用200毫克的tislelizumab (PD-1抑制剂).
- 该患者在免疫疗法过程中接受了上阴膜囊切除术.
- 临床反应和瘤复发被监测了超过24个月.
主要成果:
- 患者在8个周期的tislelizumab后实现了完全响应 (CR).
- 在免疫疗法期间安全地进行了上囊切除术.
- 在治疗后24个月以上没有观察到瘤复发.
- 在免疫治疗过程中没有发生严重的免疫相关不良事件.
结论:
- 单一治疗Tislelizumab为结石相关的膀SCC患者提供了可行的治疗选择,这些患者无法接受手术或不能耐受化疗.
- 在免疫瘤控制下,同时进行手术去除石头是可行的.
- 对这种罕见的膀癌亚型,需要对PD-1抑制剂进行进一步的研究.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.0K
相关概念视频
01:30Urinary Tract Calculi III: Medical Management
181
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
181
01:25Urinary Tract Calculi VI: Surgical Management
335
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
335
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
353
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
353
01:28Urinary Tract Calculi I: Introduction
381
Renal calculi, or kidney stones, are solid deposits of minerals and salts formed inside the kidneys. In medical terminology, "calculus" refers to the stone itself, while "lithiasis" describes the process of stone formation. Depending on their location within the urinary system, these stones may be classified as either urolithiasis, when situated within the urinary tract, or nephrolithiasis, when located within the kidneys. Each term signifies the specific impact of the stone.Predisposition...
381
01:28Urinary Tract Calculi V: Nursing Management
257
AssessmentSubjective Data: Obtain a detailed health history, including any recent or chronic urinary tract infections, periods of immobilization, previous episodes of renal calculi, and medical conditions such as gout, benign prostatic hyperplasia, or hyperparathyroidism. Review the medication history for drugs that may influence stone formation, including allopurinol, analgesics, loop diuretics, or thiazide diuretics. Document the use of long-term indwelling catheters and any past surgical...
257